Learn about other FRAGMIN indications throughout the hospital

  • Resource Center

    FRAGMIN Resource Center

    Eisai offers resources to assist you and your staff in the education and administration of FRAGMIN.

    Learn more >
  • Resource Center

    FRAGMIN Self-Injection Demo Video

    This Self-Injection Demo Video walks patients through the steps of injecting with a fixed-dose or graduated syringe.

    Learn more >
  • Resource Center

    FRAGMIN Patient Education and Administration Kits

    Educational materials, including an easy-to-understand reference chart, a step-by-step product brochure, and a how-to demonstration video, introduce patients to the use of FRAGMIN at home.

    Learn more >

FRAGMIN Education and Support

Education and support materials have been designed to assist you and your staff in the education and administration of FRAGMIN throughout the hospital in a comprehensive and efficient manner. On-site nurses can provide you and your clinicians with the support you need to continue delivering the highest quality of care possible.

Downloading this material requires that you install Adobe® Reader®, which you can download for free by clicking here.

Dosing and Administration Poster

Dosing and Administration Guides
FRAGMIN Leave-behind Dosing and Administration Guides are designed to offer healthcare providers a quick reference for the dosing and administration of FRAGMIN for the range of indications FRAGMIN covers throughout the hospital.

Download Clinic Dosing and Administration Guide

Download Hospital Dosing and Administration Guide

Dosing and Administration Guides

Dosing and Administration Poster
FRAGMIN® (dalteparin sodium injection) Dosing and Administration Poster offers a quick reference for your staff of the Full Prescribing Information, Important Safety Information, and procedures of administration and dosing options of FRAGMIN.

Request a Dosing and Administration Poster from your FRAGMIN representative.

Dosing and Administration Slide Rule

Dosing and Administration Slide Rule
FRAGMIN Leave-behind Dosing Slide Rule offers you a convenient method for determining appropriate FRAGMIN dosing. It focuses on the FRAGMIN oncology and cardiology weight-based dosing options in an
easy-to-use slide rule format.

Request a FRAGMIN Dosing Slide Rule from your FRAGMIN representative.

Patient Education and Administration Kit

Patient Education and Administration Kits
FRAGMIN Patient Education and Administration Kits introduce patients to the usage of FRAGMIN at home through materials such as an
easy-to-understand reference chart, a step-by-step product brochure, and a how-to demonstration video.

Request Patient Education and Administration Kits from your FRAGMIN representative.



Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

  • Use of indwelling epidural catheters
  • Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
  • A history of traumatic or repeated epidural or spinal punctures
  • A history of spinal deformity or spinal surgery

Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.

Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.

  • FRAGMIN is contraindicated in patients with active major bleeding, history of heparin induced thrombocytopenia, hypersensitivity to dalteparin sodium, heparin, or pork products.
  • FRAGMIN is contraindicated in patients undergoing epidural/neuraxial anesthesia as a treatment for unstable angina and non-Q-wave MI and for prolonged VTE prophylaxis due to an increased risk of bleeding associated with the dosage of FRAGMIN recommended for these indications.
  • FRAGMIN, like other anticoagulants, should be used with extreme caution in patients who have an increased risk of hemorrhage; bleeding can occur at any site during therapy. An unexpected drop in hematocrit or blood pressure should lead to a search for a bleeding site.
  • FRAGMIN should be used with caution in patients with bleeding diathesis, thrombocytopenia or platelet defects, severe liver or kidney insufficiency, hypertensive or diabetic retinopathy, and recent gastrointestinal bleeding.
  • FRAGMIN should be used with extreme caution in patients with history of heparin-induced thrombocytopenia.
    In FRAGMIN clinical trials supporting non-cancer indications, platelet count of <50,000/mm3 occurred in <1% of patients.
    In FRAGMIN clinical trials supporting the extended treatment of symptomatic VTE in patients with cancer, platelet counts of <100,000/mm3 occurred in 13.6% of patients, including 6.5% who also had platelet counts less than 50,000/mm3. In the same clinical trial, thrombocytopenia was reported as an adverse event in 10.9% of patients in the FRAGMIN arm and 8.1% of patients in the oral anticoagulant arm. FRAGMIN dose was decreased or interrupted in patients whose platelet counts fell below 100,000/mm3.
  • Thrombocytopenia of any degree should be monitored closely. Heparin-induced thrombocytopenia can occur with administration of FRAGMIN. The incidence of this complication is unknown at present. In clinical practice, rare cases of thrombocytopenia with thrombosis have also been observed.
  • Each multiple-dose vial of FRAGMIN contains benzyl alcohol as a preservative. Benzyl alcohol has been reported to be associated with a fatal “Gasping Syndrome” in premature infants. Because benzyl alcohol may cross the placenta, use caution when administering FRAGMIN preserved with benzyl alcohol to pregnant women. If anticoagulation with FRAGMIN is needed during pregnancy, use preservative-free formulations, where possible.
  • Periodic routine complete blood counts, including platelet count, blood chemistry, and stool occult blood tests are recommended during the course of treatment with FRAGMIN.
  • The most commonly reported side effect is hematoma at the injection site.
  • Allergic reactions (i.e., pruritus, rash, fever, injection site reaction, bulleous eruption) have occurred. A few cases of anaphylactoid reactions have been reported.
  • Use FRAGMIN with care in patients receiving oral anticoagulants, platelet inhibitors, and thrombolytic agents because of increased risk of bleeding.
  • FRAGMIN cannot be used interchangeably (unit for unit) with unfractionated heparin or other low molecular weight heparins.
  • FRAGMIN® Injection is not intended for intramuscular administration.
  • For more information about FRAGMIN please see Full Prescribing Information


When patients are at risk for thrombotic complications1

Prophylaxis of DVT

  • Medical
    • For patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness
  • Orthopedics
    • In patients undergoing hip replacement surgery
  • Surgery
    • In patients undergoing abdominal surgery who are at risk for thromboembolic complications

Treatment of symptomatic VTE

  • Oncology
    • Extended treatment of symptomatic VTE to reduce the recurrence of VTE in patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for 6 months
    • FRAGMIN is not indicated for the acute treatment of VTE

Prophylaxis of ischemic complications

  • Cardiology
    • Prophylaxis of ischemic complications in unstable angina (UA) and non–Q-wave myocardial infarction (NQWMI) when concurrently administered with aspirin therapy

Reference: 1. FRAGMIN prescribing information. Eisai Inc.; 2010.